Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors

Fig. 6

Activation of STAT3 in the tumor-associated stroma. Box plot showing the expression of STAT3 in different cell populations from a cohort of CRC patients from counfoundR (A-B). Enrichment plot showing IL6/JAK/STAT3 in a CRC cohort comparing epithelial and fibroblas t expression using confoundR (C). Box plot showing the expression of pSTAT3tyr705 within the tumor and stromal compartments of cohort 1 (D). Box plot showing the expression of pSTAT3tyr705 within the stroma relative to TSP status of cohort 1 (E). Kaplan Meier survival curve showing the association between stromal pSTAT3 and CSS in cohort 1 (F). Scatter plot showing the association between pSTAT3 expression within the tumor and stroma of cohort 1 (G). Kaplan Meier survival curve showing the association between a combined tumor and stromal score for pSTAT3tyr705 and CSS in cohort 1 (H). Brightfield images of untreated/AZD1480 treated CCD18Co colorectal fibroblasts (I). Bar chart showing the effect of AZD1480 on cell viability of CCD18Co cells (J) and a patient-derived CAF primary cell line (K). Representative images of IF staining for MHC1 in HCT116 cells grown as a monoculture and as a coculture with CAFs (L) Representative images of IF staining for β-catenin and programmed death ligand 1 (PDL1) in HCT116 cells grown as a monoculture, as a coculture with CAFs treated with vehicle control or AZD1480 (M). Significance set to p < 0.05*, p < 0.005**, p < 0.0005***, p < 0.00005****

Back to article page